iiinova — where your digital self keeps evolving

genomicscow.bsky.social @genomicscow.bsky.social · 11/07/2026

Conferences yesterday: folks on their phone doing emails or social Conferences today: folks on their phones checking chat AIs to figure out what the speaker is going on about 🐮

000

genomicscow.bsky.social @genomicscow.bsky.social · 08/06/2026

Tone deaf, indeed. Other vendors hopefully cracking down on their antibody validation teams as we speak!

020

genomicscow.bsky.social @genomicscow.bsky.social · 14/05/2026

The unspoken beneficiaries of Chat GPT are the newly brought-in CEOs and other senior managers to a company where they can’t be seen to ask the dumb questions on the technology or biology 🐮

000

genomicscow.bsky.social @genomicscow.bsky.social · 13/04/2026

AGBT and ABRF are over… How many of you remember there’s a 10x announcement coming up, on Saturday as well!

000

genomicscow.bsky.social @genomicscow.bsky.social · 10/04/2026

Thanks for the learnings I’ll take this one off of my list

100

genomicscow.bsky.social @genomicscow.bsky.social · 10/04/2026

“impossible” suggests an iterative improvement 🤗

000

genomicscow.bsky.social @genomicscow.bsky.social · 10/04/2026

NovaSeq X 1.4 software upgrades customer priority lists are the new way Illumina can treat its premium customers now that they are trying to be more disciplined with discounting 🫠

010

genomicscow.bsky.social @genomicscow.bsky.social · 02/03/2026

18 months is the new 18 weeks That’s what you can tell your boss now if you do genomics the agbt26 way

000

genomicscow.bsky.social @genomicscow.bsky.social · 01/03/2026

Illumina alumni have always been hot-to-hire in the market, but right now they all want to hire Roche (SBX) alumni

000

genomicscow.bsky.social @genomicscow.bsky.social · 25/02/2026

Looked like Berkeley Lights at first glance

010

genomicscow.bsky.social @genomicscow.bsky.social · 23/02/2026

Lots of new genomics product announcements! 🚨 Sales/marketing promoting on LinkedIn these products they sell. Ho hum. Recruiters promoting on LinkedIn these products from companies they want to recruit for. Cringe?

000

genomicscow.bsky.social @genomicscow.bsky.social · 19/02/2026

What changed element’s thesis that the mid throughput market is to be built upon? Comparing their installs with NextSeqs why do they think they have a better chance against Nova? Illumina would rather fight only at the Nova side of the business, and be relieved to sweep up low and mid throughput

100

genomicscow.bsky.social @genomicscow.bsky.social · 11/02/2026

Does the rate of X/Bluesky usage correlate with conference talks?

000

genomicscow.bsky.social @genomicscow.bsky.social · 27/01/2026

Like in politics, the middle powers of genomics might need to band together a bit more Middle power companies are those could get bought by the super powers (Illumina, Thermo, Danaher, etc) If they don’t meet in Davos they should at least meet in Orlando

000

genomicscow.bsky.social @genomicscow.bsky.social · 02/01/2026

Good to know society still wants us to

010

genomicscow.bsky.social @genomicscow.bsky.social · 12/12/2025

Instrument-free options for expanding the menu are what’s needed for vendors to survive this environment. It won’t score the revenue beats but it’ll reduce the lumpiness

000

genomicscow.bsky.social @genomicscow.bsky.social · 09/12/2025

Job interview question: Please recite your 96 times table

000

genomicscow.bsky.social @genomicscow.bsky.social · 20/11/2025

AGBT is elitist, over-priced, demands that a written justification for my attendance, in a red state… Woohoo I got accepted!

030

genomicscow.bsky.social @genomicscow.bsky.social · 06/11/2025

The research community often moves by methods, maybe as much as it moves by questions Affinity approaches expands the proteomics tent. Then they will ask more granular questions that direct approaches can answer. Walk, then run, etc

010

genomicscow.bsky.social @genomicscow.bsky.social · 26/10/2025

I don’t disagree with your theme but in context if that quote it’s worth remembering that Pharma usually outputs antibodies to drug targets

010

genomicscow.bsky.social @genomicscow.bsky.social · 15/09/2025

It could still be 500 slides. But presented at the speed of his brain!

010

genomicscow.bsky.social @genomicscow.bsky.social · 20/08/2025

What took Xenium so long to get protein panels out? These were touted several years ago - Resources taken from Xenium? - Resources in Xenium but needed for other features or bugs to fix? - Chemistry was poorly optimized for dev teams to finalized? But one answer can’t be true: lack of demand.

000

genomicscow.bsky.social @genomicscow.bsky.social · 13/08/2025

“Cry, the beloved country, these things are not yet at an end” Alan Paton

031

genomicscow.bsky.social @genomicscow.bsky.social · 13/08/2025

Just saw that Somalogic nabbed a big win 👏 1. Big non European cohort doing proteomics 👍 2. Competition where SomaScan won 🥇 3. But now Illumina buying Somalogic to run on NGS🦈 4. But why generate this data on a microarray platform w limited future? 🤷‍♀️ investors.standardbio.com/news-release...

investors.standardbio.com

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study | Standard BioTools Inc.

The Investor Relations website contains information about Standard BioTools Inc.'s business for stockholders, potential investors, and financial analysts.

020

genomicscow.bsky.social @genomicscow.bsky.social · 27/07/2025

Your users can simply choose on price/performance

000

genomicscow.bsky.social @genomicscow.bsky.social · 27/07/2025

Regardless of the results, why would you NOT offer PIPseq as a service given not barriers to start this protocol?

200

genomicscow.bsky.social @genomicscow.bsky.social · 14/07/2025

Company posting message about how important their products are …and backing this up with a picture of their Chief-anything-Officer with a quote about how much we should believe this #imsold! 🐮

010

genomicscow.bsky.social @genomicscow.bsky.social · 11/07/2025

Now waiting for some GWAS studies followed to find cool genes, followed by analyses on how coolness is confounded by mating behavior 😎 www.nytimes.com/2025/06/30/w...

nytimes.com

What Makes Someone Cool? A New Study Offers Clues.

020

genomicscow.bsky.social @genomicscow.bsky.social · 23/06/2025

Where illumina could struggle culturally is to do product development beyond the current somalogic kit going around. They indicate this so let’s see

100

genomicscow.bsky.social @genomicscow.bsky.social · 23/06/2025

I think it’s an old perception that illumina reps can only sell boxes. Illumina run rate is pretty high per instruments and they are less focused on new sites but upgrading and developing business around each sequencer

100

genomicscow.bsky.social @genomicscow.bsky.social · 23/06/2025

So we will see illumina at HUPO this year?

000

genomicscow.bsky.social @genomicscow.bsky.social · 23/06/2025

In all cases you already know that library prep balloons well above sequencing costs compared to classic methods illumina is already doing prep kits for

100

genomicscow.bsky.social @genomicscow.bsky.social · 23/06/2025

Like with spatial and single cell, they don’t need to, do they? They just need a bigger slice of the library prep pie

100

genomicscow.bsky.social @genomicscow.bsky.social · 10/06/2025

You’re a bright star in this sky. Keep posting!!

010

genomicscow.bsky.social @genomicscow.bsky.social · 06/06/2025

Such timing. Not the LinkedIn part though, that’s still boring

000

genomicscow.bsky.social @genomicscow.bsky.social · 06/06/2025

Call me heartless if you want, but I’m a bit jaded with this pitch: “Someone I knew had a disease, so I started a company…”

030

genomicscow.bsky.social @genomicscow.bsky.social · 04/06/2025

Imagine if people were honest on LinkedIn: Instead of congratulating someone on their new role, “This person burned their bridges” Till then, LinkedIn is just one big self-advertising platform 🐮

020

genomicscow.bsky.social @genomicscow.bsky.social · 03/06/2025

So you can hide a wedding ring in there and…

100

genomicscow.bsky.social @genomicscow.bsky.social · 03/06/2025

Were you not allowed to enter the mass spec conference? 🤣

100

genomicscow.bsky.social @genomicscow.bsky.social · 24/05/2025

In the future (next year) we have live captioning #eshg2025

000

genomicscow.bsky.social @genomicscow.bsky.social · 23/05/2025

Milan in May ☀️ or Boston in October? #eshg25 (Actually Boston is simply beautiful in October) 🍁

000

Reposted by @genomicscow.bsky.social

Jake Wintermute @synbio1.bsky.social · 16/05/2025

You can’t eat microchips. Social media can’t heal the sick. B2B SaaS will never love you The final measure of any technology is the value it creates, directly or indirectly, for living things. In this sense, biology is everyone’s mission

194

genomicscow.bsky.social @genomicscow.bsky.social · 16/05/2025

- Don’t screen for a collection of unrelated diseases - Target an area that has clinical pathway already and accompanies existing test - Focus on identifying patients for more attention not less - Don’t target PCPs - Utility cannot be “live healthier”

000

genomicscow.bsky.social @genomicscow.bsky.social · 16/05/2025

So if we naively think we can develop these with a myriad of techniques available now and demonstrate POC vs genomics, we will get impatient again about the sluggish uptake

100

genomicscow.bsky.social @genomicscow.bsky.social · 16/05/2025

Excited and bearish on proteomics risk scores. I hear how they compare favorably to polygenic risk scores But, polygenic risk scores already perform far better than incumbents Performance isn’t the issue To be clear, proteins have many advantages (dynamic, possible with existing dx infrastructure

100

genomicscow.bsky.social @genomicscow.bsky.social · 14/05/2025

Possibly the consultants did well ,though

000

genomicscow.bsky.social @genomicscow.bsky.social · 14/05/2025

A relief, followed with regret on wasting energy on emergency meetings for many, I’ll bet Meanwhile illumina isn’t likely to do well in China for a while yet, not just for instruments but probably also consumables

110

genomicscow.bsky.social @genomicscow.bsky.social · 11/05/2025

Last I read of Vinay Prasad he was generally against large genomics panels for cancer testing - though with reasonable rebuttals Wow his career really took a turn (and off!) from those days!

010

genomicscow.bsky.social @genomicscow.bsky.social · 11/05/2025

So if there measures of this paper don’t matter with unknown specificity, what should my take on it be? CVs would suggest false sense of security.

100

genomicscow.bsky.social @genomicscow.bsky.social · 11/05/2025

Thanks for sharing! How much does this change the trust levels from the mass spec community about ngs approaches in proteomics?

110